AUA 2018: Initial Clinical Testing of Ureteral Access Sheath Force Sensor to Prevent Ureteral Injuries
San Francisco, CA USA (UroToday.com) Zachary Valley from the University of California, Irvine (UCI), presented data on his team’s initial clinical findings using a ureteral access sheath force sensor (UAS-FS) during routine ureteroscopy procedure. As an introduction to his talk, Valley explained that ureteral injury is a major concern during ureteral access sheath deployment. However, the amount of force that results in clinical ureteral injury has yet to be defined.
AUA 2018: Surgical Techniques: Tips & Tricks - Robotic Partial Nephrectomy
San Francisco, CA USA (UroToday.com) Dr. Desai of the University of Southern California moderated a panel consisting of Dr. Bratslavsky from SUNY Upstate Medical University, Dr. Porter from Swedish Medical Center, and Dr. Herrell from Vanderbilt University Medical Center.
EAU 2018: Precision Medicine in Renal Cell Cancer, Can We Select The Treatment?
Copenhagen, Denmark (UroToday.com) Dr. Alessandro Volpe provided a discussion on precision medicine for patients with renal cell cancer. Precision medicine is a medical model that proposes the customization of healthcare with medical decisions, treatment and practices tailored to the individual patient. Precision medicine, specifically in patients with high risk/advanced/metastatic RCC, includes (i) selection of the optimal targeted/immunotherapy, (ii) indications for adjuvant therapy after radical nephrectomy, and (iii) indications for cytoreductive nephrectomy in the setting of metastatic RCC. Precision medicine, specifically in patients with localized RCC, includes (i) indications for nephron-sparing surgery in larger tumors (T1b-T2), (ii) indications for lymph node dissection in high-risk disease, and (iii) indications for non-surgical management in select patients.
EAU 2018: Molecular Heterogeneity Between Primary Tumors and Metastases in Renal Cell Cancer
Copenhagen, Denmark (UroToday.com) Dr. Kerstin Junker from Germany discussed the molecular heterogeneity between primary tumors and metastases. According to Dr. Junker there are three types of tumor heterogeneity, including (i) intertumor heterogeneity, (ii) intratumor heterogeneity, and (iii) heterogeneity between primary tumors and metastases. Understanding the heterogeneity of metastatic disease allows selection of therapy targets and prediction of therapy responses.
EAU 2018: Molecular and Histopathological Heterogeneity in Muscle-Invasive Bladder Cancer
Copenhagen, Denmark (UroToday.com) Dr. Antonio Lopez-Beltran from Spain gave a talk on molecular and histopathological heterogeneity in muscle invasive bladder cancer (MIBC). Dr. Lopez-Beltran started by highlighting that urothelial carcinoma has two morphologic and molecular phenotypes: non-muscle invasive bladder cancer (NMIBC; 70-80%) and MIBC (20-30%).
EAU 2018: The Critically Ill Patient with Locally Advanced Bladder Cancer – Ureterocutaneostomy? YES
Copenhagen, Denmark (UroToday.com) Dr. Armin Pycha from Bolzano, Italy provided the “yes” argument for ureterocutaneostomy in critically ill patients with locally advanced bladder cancer.
EAU 2018: The Critically Ill Patient with Locally Advanced Bladder Cancer – Ureterocutaneostomy? NO
Copenhagen, Denmark (UroToday.com) Dr. Siemer from Germany provided the rebuttal to Dr. Pycha’s “yes” for ureterocutaneostomy in the critically ill patients with locally advanced bladder cancer. As Dr. Siemer notes, when treating the critically ill patient there is a balance between survival and quality of life/potential complications.